Antibiotic Strategies for Severe Community-Acquired Pneumonia

Semin Respir Crit Care Med. 2024 Apr;45(2):187-199. doi: 10.1055/s-0043-1778641. Epub 2024 Feb 1.

Abstract

Despite advancements in health systems and intensive care unit (ICU) care, along with the introduction of novel antibiotics and microbiologic techniques, mortality rates in severe community-acquired pneumonia (sCAP) patients have not shown significant improvement. Delayed admission to the ICU is a major risk factor for higher mortality. Apart from choosing the appropriate site of care, prompt and appropriate antibiotic therapy significantly affects the prognosis of sCAP. Treatment regimens involving ceftaroline or ceftobiprole are currently considered the best options for managing patients with sCAP. Additionally, several other molecules, such as delafloxacin, lefamulin, and omadacycline, hold promise as therapeutic strategies for sCAP. This review aims to provide a comprehensive summary of the key challenges in managing adults with severe CAP, focusing on essential aspects related to antibiotic treatment and investigating potential strategies to enhance clinical outcomes in sCAP patients.

Publication types

  • Review

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Community-Acquired Infections* / microbiology
  • Hospitalization
  • Humans
  • Intensive Care Units
  • Pneumonia* / drug therapy
  • Prognosis

Substances

  • Anti-Bacterial Agents